Medication-Assisted Treatment (MAT) Centers in Hawaii

Yes — a history of relapse does not disqualify you from mat. In fact, repeated relapses are a strong clinical reason to start MAT, because continued use without medication carries a much higher overdose risk. Hawaii programs routinely admit patients with complex relapse histories.

Some Hawaii programs offer a free screening or phone intake; others charge an initial assessment fee ($100–$300 self-pay). Federally qualified health centers often waive the first visit. Ask up front about assessment fees when you schedule your appointment.

Yes. Med-QUEST covers the mandated counseling component for MAT — individual therapy, group sessions, and care coordination — at participating Hawaii clinics. Reimbursement for peer-support specialists is also available under the state plan.

Yes. COBRA continues your former employer’s health plan unchanged for up to 18 months, including MAT benefits. The monthly COBRA premium is higher than a marketplace plan for most people; explore Marketplace options too before the 60-day COBRA deadline.

Yes. Hawaii hospitals routinely start buprenorphine in the ED and bridge patients to outpatient MAT. The state’s opioid-response plan funds ED warm-handoff coordinators who connect patients to MAT programs in their home zip code before discharge.

Nationwide average MAT retention is about 6–18 months; the strongest outcomes occur in patients retained beyond 12 months. Hawaii State Opioid Response data reports rising average retention since 2021 as hub-and-spoke models mature.

Call a mat clinic directly, SAMHSA’s national helpline (1-800-662-4357), or 988 for urgent help. Most Hawaii MAT programs offer same-day or next-business-day intake; the intake visit includes an assessment and your first dose or prescription.

Yes. Records are protected by 42 CFR Part 2, which is stricter than HIPAA. Your employer, family, or law enforcement cannot access your records without your specific written consent or a narrowly tailored court order. Confidentiality applies from the first visit onward.

Common side effects are usually mild and transient: nausea, constipation, headache, drowsiness, sweating, and insomnia. Most resolve within 1–2 weeks of dose stabilization. Persistent side effects are addressed by dose adjustment or switching medications at your Hawaii clinic.

Yes. Methadone and buprenorphine are the evidence-based standard of care in pregnancy, endorsed by ACOG and SAMHSA. Staying on MAT protects both mother and fetus; unmedicated withdrawal is riskier than continued MAT. Hawaii providers coordinate care with obstetrics.

No. Attending 12-step programs is optional; SMART Recovery, Women for Sobriety, Refuge Recovery, and secular support groups are all acceptable alternatives. Hawaii MAT clinicians can help you match with a peer group aligned to your values.

No. There is no public registry of MAT patients. Hawaii’s prescription drug monitoring program (PDMP) tracks controlled-substance prescriptions but is accessible only to clinicians and law enforcement with a specific investigative basis.